Back to Top
World Gastroenterology Organisation
World Gastroenterology Organisation
WGO: Facebook WGO: Twitter

Hepatitis B (HBV)

Level: Meta-analyses, Systematic reviews, Practice guidelines: 36 Abstracts

Legend: : Key Development,  : Very Important,  : Important, [no star]: Special Mention


American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute., Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31. Review. No abstract available. Erratum in: Gastroenterology. 2015 Feb;148(2):455. multiple investigator names added.
Comments: Prevention of reactivation of HBV during immunosuppression


Diagnosis and management of chronic hepatitis B in children, young people, andadults: summary of NICE guidance.
Sarri G(1), Westby M, Bermingham S, Hill-Cawthorne G, Thomas H; Guideline Development Group., BMJ. 2013 Jun 26;346:f3893. doi: 10.1136/bmj.f3893.

Comments: Guidelines for HBV


Telbivudine prevents vertical transmission from HBeAg-positive women with chronichepatitis B.
Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, Yue X, Wang GJ., Clin Gastroenterol Hepatol. 2012 May;10(5):520-6. doi: 10.1016/j.cgh.2012.01.019. Epub 2012 Feb 14.

Comments: 88 chronic HBeAg-pos pregnant women with levels of HBV DNA >6 log(10) copies/mL, and increased ALT were given telbivudine (n = 53) starting in the 2nd or 3rd trimester, or no treatment . All infants received standard immunoprophylaxis after birth.At 28 wks of age, none of the infants whose mothers received telbivudine had immunoprophylaxis failure, whereas 8.6% of the infants of control mothers did (P = .029).


Effects of maternal screening and universal immunization to preventmother-to-infant transmission of HBV.
Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, Chu CH, Ni YH, Hsu HY, Tsai PL, Chiang CL, Shyu MK, Lee PI, Chang FY, ChangMH., Gastroenterology. 2012 Apr;142(4):773-781.e2. doi: 10.1053/j.gastro.2011.12.035. Epub 2011 Dec 23.

Comments: In addition to HBV vaccines, HBIG was given to all 583 children with HBeAg-pos mothers and to 723 of 1773 children with HBeAg-neg mothers.Children with HBeAg-pos mothers tested more often positive for aHBc (16.76% vs 1.58%) and aHBs (9.26% vs 0.29%) than with HBeAg-neg mothers. Chronicity was higher with HBeAg-pos mothers than with HBeAg-negative mothers (54% vs 17%). HBIG given to infants born to HBeAg-neg mothers did not appear to reduce the rate of chronic HBV infection, but might prevent infantile fulminant hepatitis and thus remains advocated.


Entecavir plus tenofovir combination as rescue therapy in pre-treated chronichepatitis B patients: an international multicenter cohort study.
Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P., J Hepatol. 2012 Mar;56(3):520-6. doi: 10.1016/j.jhep.2011.09.018. Epub 2011 Oct 26.

Comments: Combination of entecavir and tenofovir in CHB patients with viral resistance patterns was efficient, safe, and well tolerated in patients with and without advanced liver disease


Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis.
Xiao G, Yang J, Yan L., Hepatology. 2015 Jan;61(1):292-302. doi: 10.1002/hep.27382. Epub 2014 Nov 24. Review.
Comments: Liver fibrosis: diagnosis


American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
Perrillo RP, Gish R, Falck-Ytter YT., Gastroenterology. 2015 Jan;148(1):221-244.e3. doi: 10.1053/j.gastro.2014.10.038. Epub 2014 Oct 31. Review. No abstract available.
Comments: idem


Telbivudine improves renal function in patients with chronic hepatitis B.
Gane EJ(1), Deray G(2), Liaw YF(3), Lim SG(4), Lai CL(5), Rasenack J(6), WangY(7), Papatheodoridis G(8), Di Bisceglie A(9), Buti M(10), Samuel D(11), UddinA(12), Bosset S(13), Trylesinski A(13)., Gastroenterology. 2014 Jan;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031. Epub 2013 Sep 22.

Comments: In compensated HBV cirrhosis with baseline eGFRs of 60-89 mL/min/1.73 m2, or > 50 yrs, and in decompensated cirrhosis, long-term telbivudine therapy was associated with a sustained improvement of renal function.


Risk factors for long-term persistence of serum hepatitis B surface antigenfollowing acute hepatitis B virus infection in Japanese adults.
Ito K(1), Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, Arase Y,Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N,Mizokami M; Japanese AHB Study Group., Hepatology. 2014 Jan;59(1):89-97. doi: 10.1002/hep.26635. Epub 2013 Nov 20.

Comments: Genotype A was an independent risk factor for slower disappearance of HBsAg and for more progression to chronic hepatitis following acute HBV infection.


Sodium-dependent taurocholic cotransporting polypeptide: a candidate receptor forhuman hepatitis B virus.
Seeger C(1), Mason WS., Gut. 2013 Aug;62(8):1093-5. doi: 10.1136/gutjnl-2013-304594. Epub 2013 Mar 29.

Comments: Comment on the work of Yan et al, sowing that the Sodium-dependent taurocholic cotransporting polypeptide (NTCP) is a candidate receptor for human hepatitis B virus.


High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAgseroconversion in chronic hepatitis B.
Ma SW, Huang X, Li YY, Tang LB, Sun XF, Jiang XT, Zhang YX, Sun J, Liu ZH, Abbott WG, Dong YH, Naoumov NV, Hou JL., J Hepatol. 2012 Apr;56(4):775-81. doi: 10.1016/j.jhep.2011.10.020. Epub 2011 Dec 13.

Comments: Serum IL-21 levels were measured in HBeAg-positive chronic hepatitis B (CHB) patients under telbivudine treatment:serum IL-21 levels at week 12 were significantly higher in patients who did achieve a complete response. Serum IL-21 levels may be a biomarker for HBeAg seroconversion, and IL-21 may also have a role in immunotherapy for CHB.


Polymorphisms near IL28B and serologic response to peginterferon inHBeAg-positive patients with chronic hepatitis B.
Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL., Gastroenterology. 2012 Mar;142(3):513-520.e1. doi: 10.1053/j.gastro.2011.11.025. Epub 2011 Nov 19.

Comments: IL28B genotype was significantly associated with HBeAg seroconversion at the end of treatment with PEG-IFN (P < .001); the adjusted odds ratio for seroconversion was 3.16 (95% C], 1.26-8.52; P = .013) for AA versus AG/GG


Effectiveness of hepatitis B treatment in clinical practice.
Scaglione SJ, Lok AS., Gastroenterology. 2012 May;142(6):1360-1368.e1. doi:10.1053/j.gastro.2012.01.044.

Comments: The efficacy of hepatitis B treatment is reviewed. The efffectiveness of the antiviral treatments are compared, but it is clear that having efficacious treatments alone will only have a small impact on the global health burden of hepatitis B. The importance of educating the public and the medical community and coordination of care is very important.


Tenofovir and entecavir are the most effective antiviral agents for chronichepatitis B: a systematic review and Bayesian meta-analyses.
Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ, Krahn M., Gastroenterology. 2010 Oct;139(4):1218-29. Epub 2010 Jun 20.


Introduction to chronic hepatitis B infection.
TL Wright, Am J Gastroenterol. 2006:S1-6


Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan.
CJ Liu, SC Lo, JH Kao, PT Tseng, MY Lai, YH Ni, SH Yeh, PJ Chen, DS Chen, J Hepatol. 2006 Jan:39-46


Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIBvaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis Band Haemophilus influenzae B (HIB).
Bar-On ES, Goldberg E, Hellmann S, Leibovici L., Cochrane Database Syst Rev. 2012 Apr 18;4:CD005530. doi:10.1002/14651858.CD005530.pub3.

Comments: The WHO recommends routine infant immunisation against Haemophilus influenzae type B (HIB) and combined diphtheria-tetanus-pertussis (DTP)-hepatitis B virus vaccination. The effectiveness and safety of the combined DTP-HBV-HIB was examined vs HIB separate.A meta-analysis of 20 studies with 5874 participants each could not reach conclusive results.


Hepatitis B virus infection in dialysis patients.
PN Wong, TT Fung, SK Mak, KY Lo, GM Tong, Y Wong, CK Loo, EK Lam, AK Wong, J Gastroenterol Hepatol. 2005 Nov:1641-51


Highly endemic hepatitis B infection in rural Vietnam.
VT Nguyen, ML McLaws, GJ Dore, J Gastroenterol Hepatol. 2007 Jul 20


Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California.
SY Lin, ET Chang, SK So, Hepatology. 2007 Oct:1034-40


Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review.
Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, Sun W, Zhao X, Yang X, Zhang L,Lu W, Teng J, An Y., Arch Pediatr Adolesc Med. 2011 Sep;165(9):837-46. Epub 2011 May 2.


Global epidemiology of hepatitis B and hepatitis C in people who inject drugs:results of systematic reviews.
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L., Lancet. 2011 Aug 13;378(9791):571-83. Epub 2011 Jul 27.


Meta-analysis: reduction in hepatic events following interferon-alfa therapy ofchronic hepatitis B.
Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL., Aliment Pharmacol Ther. 2010 Nov;32(9):1059-68. doi:10.1111/j.1365-2036.2010.04447.x. Epub 2010 Aug 29.


Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients.
Fabrizi F, Dixit V, Messa P, Martin P., Aliment Pharmacol Ther. 2010 Sep;32(6):756-62. doi:10.1111/j.1365-2036.2010.04410.x. Epub 2010 Jul 20.


Intradermal vs intramuscular vaccine against hepatitis B infection in dialysispatients: a meta-analysis of randomized trials.
Fabrizi F, Dixit V, Messa P, Martin P., J Viral Hepat. 2010 Aug 31. [Epub ahead of print]


A randomized trial of peginterferon alpha-2a with or without ribavirin forHBeAg-negative chronic hepatitis B.
Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K,Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE,Janssen HL; PARC Study Group., Am J Gastroenterol. 2010 Aug;105(8):1762-9. Epub 2010 May 11.


Contemporary clinical research of traditional Chinese medicines for chronichepatitis B in China: an analytical review.
Zhang L, Wang G, Hou W, Li P, Dulin A, Bonkovsky HL., Hepatology. 2010 Feb;51(2):690-8.


Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries.
VT Nguyen, K Razali, J Amin, MG Law, GJ Dore, J Gastroenterol Hepatol. 2007 Jul 1


Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination.
LY Wang, HH Lin, J Hepatol. 2007 Jun:1018-25


Hepatitis B immunisation in Britain: time to change?
J Banatvala, P Van Damme, N Emiroglu, BMJ. 2006 Apr 8:804-5


Hepatitis B vaccination rate of homeless children in Baltimore.
K Schwarz, B Garrett, J Lamoreux, YD Bowser, C Weinbaum, MJ Alter, J Pediatr Gastroenterol Nutr. 2005 Aug:225-9


Intrafamilial spread of hepatitis B virus infection in Greece.
EK Zervou, NK Gatselis, E Xanthi, K Ziciadis, SP Georgiadou, GN Dalekos, Eur J Gastroenterol Hepatol. 2005 Sep:911-5


Long-term efficacy of hepatitis B vaccination in healthcare workers of Oil Company Hospital, Tehran, Iran (1989-2005).
SM Alavian, S Mansouri, M Abouzari, S Assari, MS Bonab, SM Miri, Eur J Gastroenterol Hepatol. 2008 Feb:131-4


Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease.
F Fabrizi, SV Ganeshan, V Dixit, P Martin, Aliment Pharmacol Ther. 2006 Sep 1:789-96


Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease.
F Fabrizi, V Dixit, P Martin, Aliment Pharmacol Ther. 2006 Jun 1:1559-66


Response to vaccination against hepatitis B in patients with Behcet's disease.
E Erkek, E Ayaslioglu, AB Erkek, GS Kurtipek, Y Bagci, J Gastroenterol Hepatol. 2005 Oct:1508-11